Why Patients Decline Genomic Sequencing Studies: Experiences from the CSER Consortium
- 367 Downloads
Clinical and research settings are increasingly incorporating genomic sequencing (GS) technologies. Previous research has explored reasons for declining genetic testing and participation in genetic studies; however, there is a dearth of literature regarding why potential participants decline participation in GS research, and if any of these reasons are unique to GS. This knowledge is essential to promote informed decision-making and identify potential barriers to research participation and clinical implementation. We aggregated data from seven sites across the National Institutes of Health’s Clinical Sequencing Exploratory Research (CSER) consortium on each project’s procedures for recruitment, and rates of and reasons for decline. Data were analyzed using descriptive statistics. The decline rate for enrollment at the seven CSER sites ranged from 12 to 64% (median 28%) and varied based on age and disease status. Projects differed in their protocols for approaching potential participants and obtaining informed consent. Reasons for declining GS research were reported for 1088 potential participants. Commonly cited reasons were similar to those reported for clinical single gene testing and non-GS genetic research. The most frequently cited reason for decline was study logistics (35%); thus, addressing logistical barriers to enrollment may positively impact GS study recruitment. Privacy and discrimination concerns were cited by 13% of decliners, highlighting the need for researchers and providers to focus educational efforts in this area. The potential psychological burden of pursuing and receiving results from GS and not wanting to receive secondary findings, a concern specific to GS, have been cited as concerns in the literature. A minority of potential participants cited psychological impact (8%) or not wanting to receive secondary findings (2%) as reasons for decline, suggesting that these concerns were not major barriers to participation in these GS studies. Further research is necessary to explore the impact, if any, of different participant groups or study protocols on rates of decline for GS studies. Future studies exploring GS implementation should consider using standardized collection methods to examine reasons for decline in larger populations and more diverse healthcare settings.
KeywordsExome sequencing Genome sequencing Reason for decline Rate of decline Clinical Sequencing Exploratory Research (CSER) consortium
We thank Gail Jarvik and Kurt Christensen for their review and comments on drafts of this paper.
CSER Coordinating Center U01HG007307; Hudson Alpha UM1HG007301; NCGenes U01HG006487; Next Medicine U01HG006507; BASIC3 U01HG006485; MedSeq U01HG006500; NextGen UM1HG007292; PediSeq U01HG006546; Columbia Return of Results study and Genomic Consent study R21 HG006596, R01 HG006600, P50 HG007257; and ClinSeq® are supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.
Compliance with Ethical Standards
Conflict of Interest
Laura M. Amendola, Jill O. Robinson, Ragan Hart, Sawona Biswas, Kaitlyn Lee, Barbara A. Bernhardt, Kelly East, Marian J. Gilmore, Tia L. Kauffman, Katie L. Lewis, Myra Roche, Sarah Scollon, Julia Wynn, and Carrie Blout declare that they have no conflict of interest.
Human Studies and Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). For this type of study, formal consent is not required.
- Armstrong, K., Weber, B., FitzGerald, G., Hershey, J. C., Pauly, M. V., Lemaire, J., Subramanian, K., & Asch, D. A. (2003). Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. American Journal of Medical Genetics. Part A, 120a(3), 359–364. https://doi.org/10.1002/ajmg.a.20025.CrossRefPubMedGoogle Scholar
- Berg, J. S., Amendola, L. M., Eng, C., Van Allen, E., Gray, S. W., Wagle, N., et al. (2013). Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genetics in Medicine, 15(11), 860–867. https://doi.org/10.1038/gim.2013.133.CrossRefPubMedPubMedCentralGoogle Scholar
- Bombard, Y., Penziner, E., Suchowersky, O., Guttman, M., Paulsen, J. S., Bottorff, J. L., & Hayden, M. R. (2008). Engagement with genetic discrimination: concerns and experiences in the context of Huntington disease. European Journal of Human Genetics, 16(3), 279–289. https://doi.org/10.1038/sj.ejhg.5201937.CrossRefPubMedGoogle Scholar
- Close, S., Smaldone, A., Fennoy, I., Reame, N., & Grey, M. (2013). Using information technology and social networking for recruitment of research participants: experience from an exploratory study of pediatric Klinefelter syndrome. Journal of Medical Internet Research, 15(3), e48. https://doi.org/10.2196/jmir.2286.CrossRefPubMedPubMedCentralGoogle Scholar
- Foster, C., Evans, D. G., Eeles, R., Eccles, D., Ashley, S., Brooks, L., et al. (2004). Non-uptake of predictive genetic testing for BRCA1/2 among relatives of known carriers: attributes, cancer worry, and barriers to testing in a multicenter clinical cohort. Genetic Testing, 8(1), 23–29. https://doi.org/10.1089/109065704323016003.CrossRefPubMedGoogle Scholar
- Gilmore, M. J., Schneider, J., Davis, J. V., Kauffman, T. L., Leo, M. C., Bergen, K., Reiss, J. A., Himes, P., Morris, E., Young, C., McMullen, C., Wilfond, B. S., & Goddard, K. A. (2017). Reasons for declining preconception expanded carrier screening using genome sequencing. Journal of Genetic Counseling, 26, 971–979. https://doi.org/10.1007/s10897-017-0074-y.CrossRefPubMedGoogle Scholar
- Green, R. C., Goddard, K. A., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., et al. (2016). Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. American Journal of Human Genetics, 98(6), 1051–1066. https://doi.org/10.1016/j.ajhg.2016.04.011.CrossRefPubMedPubMedCentralGoogle Scholar
- Hall, M. A., McEwen, J. E., Barton, J. C., Walker, A. P., Howe, E. G., Reiss, J. A., Power, T. E., Ellis, S. D., Tucker, D. C., Harrison, B. W., McLaren, G. D., Ruggiero, A., & Thomson, E. J. (2005). Concerns in a primary care population about genetic discrimination by insurers. Genetics in Medicine, 7(5), 311–316.CrossRefGoogle Scholar
- Hayden, S., Mange, S., Duquette, D., Petrucelli, N., & Raymond, V. M. (2017). Large, prospective analysis of the reasons patients do not pursue BRCA genetic testing following genetic counseling. Journal of Genetic Counseling, 26, 859–865. https://doi.org/10.1007/s10897-016-0064-5.CrossRefPubMedGoogle Scholar
- Himes, P., Kauffman, T. L., Muessig, K. R., Amendola, L. M., Berg, J. S., Dorschner, M. O., Gilmore, M., Nickerson, D. A., Reiss, J. A., Richards, C. S., Rope, A. F., Simpson, D. K., Wilfond, B. S., Jarvik, G. P., & Goddard, K. A. (2017). Genome sequencing and carrier testing: decisions on categorization and whether to disclose results of carrier testing. Genetics in Medicine, 19, 803–808. https://doi.org/10.1038/gim.2016.198.CrossRefPubMedPubMedCentralGoogle Scholar
- Lazarin, G. A., Detweiler, S., Nazareth, S. B., & Ashkinadze, E. (2016). Genetic counselors’ perspectives and practices regarding expanded carrier screening after initial clinical availability. Journal of Genetic Counseling, 25(2), 395–404. https://doi.org/10.1007/s10897-015-9881-1.CrossRefPubMedGoogle Scholar
- Mackley, M. P., Fletcher, B., Parker, M., Watkins, H., & Ormondroyd, E. (2017). Stakeholder views on secondary findings in whole-genome and whole-exome sequencing: a systematic review of quantitative and qualitative studies. Genetics in Medicine, 19(3), 283–293. https://doi.org/10.1038/gim.2016.109.CrossRefPubMedGoogle Scholar
- Peterson, E. A., Milliron, K. J., Lewis, K. E., Goold, S. D., & Merajver, S. D. (2002). Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiology, Biomarkers & Prevention, 11(1), 79–87.Google Scholar
- Robinson, J. O., Carroll, T. M., Feuerman, L. Z., Perry, D. L., Hoffman-Andrews, L., Walsh, R. C., et al. (2016). Participants and study decliners’ perspectives about the risks of participating in a clinical trial of whole genome sequencing. Journal of Empirical Research on Human Research Ethics, 11(1), 21–30. https://doi.org/10.1177/1556264615624078.CrossRefPubMedPubMedCentralGoogle Scholar
- Schneider, J. L., Goddard, K. A., Davis, J., Wilfond, B., Kauffman, T. L., Reiss, J. A., et al. (2016). “Is It Worth Knowing?” focus group participants’ perceived utility of genomic preconception carrier screening. Journal of Genetic Counseling, 25(1), 135–145. https://doi.org/10.1007/s10897-015-9851-7.CrossRefPubMedGoogle Scholar
- Scollon, S., Bergstrom, K., Kerstein, R. A., Wang, T., Hilsenbeck, S. G., Ramamurthy, U., Gibbs, R. A., Eng, C. M., Chintagumpala, M. M., Berg, S. L., McCullough, L. B., McGuire, A. L., Plon, S. E., & Parsons, D. W. (2014). Obtaining informed consent for clinical tumor and germline exome sequencing of newly diagnosed childhood cancer patients. Genome Medicine, 6(9), 69. https://doi.org/10.1186/s13073-014-0069-3.CrossRefPubMedPubMedCentralGoogle Scholar
- Shahmirzadi, L., Chao, E. C., Palmaer, E., Parra, M. C., Tang, S., & Gonzalez, K. D. (2014). Patient decisions for disclosure of secondary findings among the first 200 individuals undergoing clinical diagnostic exome sequencing. Genetics in Medicine, 16(5), 395–399. https://doi.org/10.1038/gim.2013.153.CrossRefPubMedGoogle Scholar
- Sterling, R., Henderson, G. E., & Corbie-Smith, G. (2006). Public willingness to participate in and public opinions about genetic variation research: a review of the literature. American Journal of Public Health, 96(11), 1971–1978. https://doi.org/10.2105/ajph.2005.069286.CrossRefPubMedPubMedCentralGoogle Scholar
- Weiner, C. (2014). Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). American Journal of Epidemiology, 180(6), 562–564. https://doi.org/10.1093/aje/kwu217.CrossRefPubMedGoogle Scholar